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a  b  s  t  r  a  c  t
The recommendations proposed by the Sjögren’s Syndrome Committee of the Brazilian Soci-
ety  of Rheumatology for the treatment of Sjögren’s syndrome were based on a systematic
review of literature in Medline (PubMed) and the Cochrane databases until October 2014 and
on  expert opinion in the absence of studies on the subject. 131 articles classiﬁed according
to  Oxford & Grade were included. These recommendations were developed in order to guide
the  management and facilitate the access to treatment for those patients with an appropri-
ate  indication, considering the Brazilian socioeconomic context and pharmacological agents
available in this country.
© 2015 Elsevier Editora Ltda. All rights reserved.
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As recomendac¸ões propostas pela Comissão de Síndrome de Sjögren da Sociedade Brasileira
de  Reumatologia para tratamento da síndrome de Sjögren foram baseadas em uma  revisão
sistemática da literatura nas bases de dados Medline (PubMed) e Cochrane até outubro de
2014  e opinião de especialistas na ausência de artigos sobre o assunto. Foram incluídos
131  artigos classiﬁcados de acordo com Oxford & Grade. Essas recomendac¸ões foram elab-
oradas com o objetivo de orientar o manejo adequado e facilitar o acesso aos tratamentos
para aqueles pacientes com adequada indicac¸ão de recebê-los, considerando o contexto
socioeconômico brasileiro e os medicamentos disponíveis no país.
©  2015 Elsevier Editora Ltda. Todos os direitos reservados.
ntroduction
jögren’s syndrome (SS) is a relatively common autoimmune
heumatic disease, which is most common in women in the
fth decade of life.1 According to a Brazilian population study,
he prevalence of primary SS is 0.17%.2 SS can occur in associ-
tion with other autoimmune diseases such as systemic lupus
rythematosus (SLE) and rheumatoid arthritis (RA) in variable
ates, up to 22.2% in patients with RA.3,4
SS is a slowly progressive chronic disease, characterized by
 lymphocytic inﬁltrate that affects the epithelium of exocrine
mainly salivary and tear) glands, leading to a decreased pro-
uction of tears and saliva. This is a systemic disease with
igh risk of transformation to lymphoma that primarily affects
he joints, lungs, central nervous system (CNS), peripheral
ervous system (PNS) and kidneys in approximately 50% of
atients.5
More  recent studies have shown that there are subgroups
f patients with different clinical manifestations, histological
atterns (presence of germinative centers), cytokine proﬁle
nd prognosis.6,7 In the near future, better genetic8–10 and
henotypic characterization will be able to determine dif-
erent treatment patterns. But nowadays it is possible to
eﬁne treatment strategies based on symptoms (symptomatic
reatment), and on the type and severity of systemic mani-
estations. These guidelines recommend the use of EULAR Sjö-
ren’s Syndrome Disease Activity (ESSDAI), a tool validated
These recommendations were developed in order to guide
the management and facilitate the access to treatment for
those patients with an appropriate indication, considering
the Brazilian socioeconomic context and pharmacological
agents available in the country. Due to the length of this
review, speciﬁc topics such as management during pregnancy
and treatment of lymphoma associated with SS were not
addressed. The recommendations were based on studies on
primary Sjögren’s syndrome. Considering the lack of studies
in patients with association with other autoimmune diseases,
these recommendations can be extrapolated to secondary Sjö-
gren’s syndrome.
Materials  and  methods
Articles were reviewed in MEDLINE (PubMed) and the
Cochrane databases until December 2013. The manual update
was held in October 2014. The search strategy was based
on structured questions according to PICO (i.e. “Patient”,
“Intervention”, “Controls” and “Outcome”) format. These
descriptors were used for cross-searching in accordance with
the theme proposed in each of PICO questions. For all PICOs,
the ﬁlter “random” was used, limiting the search to controlled
studies. Studies published from January to October 2014 and
some case series on extraglandular manifestations were man-oth internationally11 and in Brazil,12 as criteria for disease
ctivity and response to treatment.ually included. After analyzing titles and abstracts, 131 articles
related to questions that generated the evidence that provided
the basis for these guidelines were selected (Fig. 1). The studies
448  r e v b r a s r e u m a t o l . 2 0 1 5;5 5(5):446–457
Articles identified in database
search(Medline and Cochrane)
(n=3564)
Articles in duplicate
identified (n=1118)
Articles retrieved 
(n=2446)
Articles excluded 
(n=2314)
Excluded after full text
review(weak evidence,
no epidemiological studies
and language)
(n=31)
Studies included in
the recommendations
(n=131)
Full texts manually included
(publications in 2014
and clinical case reports) 
(n=30)
Full texts  reviewed
(n=132)
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 evidFig. 1 – Flow diagram of the selection of
were classiﬁed according to Oxford & GRADE in degrees of
recommendation and strength of evidence as follows:
A: Experimental or observational studies of better consis-
tency.
B: Experimental or observational studies of lower consis-
tency.
C: Case reports (non-controlled studies).
D: Opinion devoid of a critical evaluation, based on consen-
sus, physiological studies, or animal models.
Some recommendations were based solely on the opinion
of experts from the Sjögren’s Syndrome Scientiﬁc Commit-
tee of the Brazilian Society of Rheumatology (BSR), in the
absence of studies on subjects. These recommendations were
also graded as a D level and are not preceded by the reference.
PICOs were structured by a multidisciplinary team that was
comprised of nine rheumatologists, members of the Sjögren’s
Syndrome Scientiﬁc Committee of BSR, with eight profession-
als from different areas (dentists, ophthalmologists, patholo-
gists and physiotherapists); all were members of the Expanded
Study Group on Sjögren’s Syndrome (Grupo Ampliado de Estudos
em Síndrome de Sjögren – GAESS – Brazil). The recommendations
were formulated mainly based on evidence and reviewed byence for Sjögren’s syndrome treatment.
all participants at two meetings and several rounds of commu-
nication via the Internet, from April 2013 until October 2014.
Recommendations
Based on those 14 PICOs used in this survey, we  organized
didactically 16 questions with 44 recommendations, divided
into three major topics and summarized in Figs. 2–5:
Part 1. General and patient education recommendations.
Part 2. Symptomatic management of dryness.
Part 3. Systemic treatment for glandular and systemic man-
ifestations.
Part  1.  General  and  patient  education  recommendations
Q1. What are the general recommendations based on expert
opinion?
1. The management of SS must be performed by a multidisci-
plinary team including at least a rheumatologist, a dentist
and an ophthalmologist. The rheumatologist is the refer-
ence specialist in the management of SS (D).
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Lubricant eyedrops (A)
Patient education and
preventive measures (D)
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Fig. 2 – Flowchart for the symptomatic treatment of dryness of SS.
2
3
4
5
F
g. Patients with early diagnosis and improved glandular
reserve show a better response to treatment (D).
. It is recommended that treatment strategies of systemic
manifestations are stratiﬁed according to disease severity,
based not only on clinical impression of the specialist, but
also with the use of ESSDAI. Systemic treatment should be
instituted in the face of a moderate ESSDAI (≥5). A response
to treatment was considered where a decrease of ESSDAI
≥3 points was detected (D).
. Patients with SS should avoid the use of caffeinated drinks,
alcohol and tobacco (D).. It is recommended that patients receive general educa-
tion for hygiene and measures to prevent dehydration and
irritation of mucous membranes (Table 1) (D).
Fatigue Noninflammatory
arthralgia and myalgia
Patient education (D)
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chronic pain (D)
Th
ird
lin
e
Fi
rs
t
lin
e
Se
co
nd
lin
e
ig. 3 – Flowchart for the treatment of musculoskeletal symptom
lucocorticoids.Q2. Exercise is effective in treating patients with SS?
6. Women with SS have a lower physical ability,13 and the
practice of aerobic exercise at moderate to high inten-
sity leads to the improvement of aerobic capacity, fatigue,
perceived exertion and depression.14 (B)
Q3. What are the effectiveness and safety of vaccines in
patients with SS?
7. It is recommended that general guidelines for vaccination
in patients with autoimmune diseases are followed15 (C),
and the vaccination status of the patient must be checked
at the patient baseline assessment. It is also recommended
Myositis
GC (D)
Arthritis
 Methotrexate (C)
imab (C)
Patient education (D)
Physiotherapy (D)
Corticosteroids or NSAIDs +
hydroxychloroquine (C)
s. NSAIDs, non-steroidal anti-inﬂammatory drugs; GC,
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IV Immunoglobulin
(C)
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Rituximab (C)
Immunosuppressant
(C)
Sensory PN 
sensory
neuropathy
Sensory-motor
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Fig. 4 – Flowchart for the treatment of neurological systemic manifestations. PN, peripheral polyneuropathy; CNS, central
 MP, nervous system; MS,  multiple sclerosis; GC, glucocorticoids;
to administer vaccines in stable periods of the disease;
live attenuated vaccines should be avoided. Immunization
against inﬂuenza16,17 (A) and Pneumococcus are indicated,18
(A) with application of other vaccines according to the
immunization schedule (D).
Q4. SS patients should receive supplementation with vita-
min D?
8. Vitamin D deﬁciency should be investigated and, if neces-
sary, its supplementation should be instituted16–23 (C).
Interstitial
lung
disease
Cutaneou
vasculitisBronchiolitis
Oral GC (C)
Immunosuppressant (C)
Intravenous MP + CYC (C)
GC + Immunosuppressant (C)
(azathioprine, cyclophosphamide,
mycophenolate)
Inhaled
corticosteroids
(C)
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Fig. 5 – Flowchart for the treatment of systemic kidney, lung and
tubulointerstitial nephritis; GC, glucocorticoids; MP, methylprednmethylprednisolone; CYC, cyclophosphamide.
Part  2.  Symptomatic  management  of  dryness
Q5. What is the topical treatment for dry mouth?
9. Saliva substitutes improve comfort24–31 (C) and ideally
should contain ﬂuoride, bactericides and buffered solu-
tions that help to combat bioﬁlm, the formation of caries
and candidiasis32 (D).
10. Mechanical and/or chemical gustatory stimulating
agents, for instance, hard candies and sugar-freechewing
s
TINGNvasculitis
Intravenous MP + CYC (C) K+ and HCO3-
replacement (C)
Oral or
intravenous
GC (C)
Rituximab (C)
 vasculitis manifestations. GN, glomerulonephritis; TIN,
isolone; CYC, cyclophosphamide.
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Table 1 – Patient education: measures for hygiene and
hydration of mucous membranes.
SS patients should be encouraged to drink ﬂuids frequently,
preferably water.
SS patients should be informed that tobacco, caffeine and various
medications such as diuretics, beta blockers, antidepressants
and anxiolytics, are known causes of dryness and can worsen
the glandular symptoms.
To prevent tear evaporation, the patient must avoid dry
environments, air conditioning, wind, and also activities that
decrease eye blinking, such as using the computer or reading for
a long period of time.
Patients with symptomatic dry eye should use environment
humidiﬁers, and glasses with side shields during exposure to
wind or when practicing outdoor sports.
Preventive measures for oral health aim to control bioﬁlm, caries,
loss of teeth and oral candidiasis. For this purpose, it is
important to maintain a good oral hygiene, keeping intraoral pH
(basic) with the use of buffers and restricting consumption of
sugar.
Careful oral hygiene includes the same recommendations for the
general population, with special attention to prosthesis hygiene
and choosing less abrasive products, avoiding products that
increase dryness of the mucosa, for example, toothpastes
containing sodium lauryl sulfate and the use of
alcohol-containing mouth rinse.
Removable total dental prosthesis users should daily cleaned their
dentures using a dental brush with stiff bristles with toothpaste,
switching to a soft bristles brush for oral mucosa cleaning. Once
a week, the prosthesis must be immersed in an aqueous
solution containing 1% sodium hypochlorite solution during
30 min; then the prosthesis should be rinsed in running water.
One can obtain this concentration of sodium hypochlorite by
diluting a tablespoon of chlorine bleach in a glass containing
1
1
1
23. The choice of immunosuppressive drug treatment for sys-300 mL of ﬁltered water.
gum,32 (D) may be helpful. Solutions or mouthwashes
containing malic acid, ﬂuoride and xylitol have similar
efﬁcacy to traditional stimulating agents containing citric
acid, but with the advantage of maintaining a less acid
pH.33 (B)
Q6. What is the topical treatment for dry eye?
1. The frequent use of lubricant eyedrops containing glu-
cans or carboxymethylcellulose improves comfort and
functional tests34–40 (A).  These eyedrops should be
preservative-free, hypotonic, higher colloidal osmolality
products.37,41 (A) Gel formulations are of longer dura-
tion and generate greater relief, but may cause temporary
blurred vision.
2. Topical cyclosporin 0.05% bid for 6–12 weeks is effective for
symptomatic and functional improvement of dry eye42–56
(A).  The occurrence of eye irritation is common; thus, this
drug is recommended at the lowest effective concentra-
tion (0.05%)55 (A).
3. Topical glucocorticoids can be used for the most symp-
tomatic cases57,58 (A) for a limited period, because of the
risk subcapsular cataract, glaucoma and infection34 (D).
Non-steroidal anti-inﬂammatory drugs (NSAIDs) must
not be routinely used, due to the high risk of corneal
perforation59,60 (D). 5;5 5(5):446–457 451
14. Lacrimal puncta occlusion improves symptoms and out-
comes of ocular tear tests. This strategy is superior to
lubricant eyedrops, and is indicated in severe cases refrac-
tory to topical treatment with eyedrops61–65 (A).
Q7. What are the effectiveness and safety of muscarinic
agonists and mucolytics in systemic symptomatic treatment
of dryness?
15. Muscarinic agonists such as pilocarpine (5 mg  bid, qid) and
cevimeline (30 mg,  tid), are more  beneﬁcial in the symp-
tomatic treatment of dry mouth66–69 (A),  but they may
also be useful in treating moderate to severe41 (D) dry
eye66,67,69–73 (A).
16. It is recommended that the dose and the range of pilo-
carpine be adjusted as tolerated66,67 (A).
17. Although not available in Brazil, cevimeline is the safest
muscarinic agonist, with lower rates of side effects and
of treatment discontinuation, thanks to a more  selective
action on M3 receptors74,75 (C).
18. The most frequent side effect of muscarinic agonists is
sweating69,72,74 (A).  One should be aware of the contraindi-
cations for the use of muscarinic agonists, especially
pilocarpine, in asthma and cardiac disease patients41 (D).
19. The mucolytic agent N-acetylcysteine, at a dose of 200 mg
tid, may be an option for muscarinic agonists in patients
with intolerance, and also in patients with dryness in
other places, such as the skin, vagina and airways76 (A).
Q8. What are the effectiveness and safety of supplemen-
tation with fatty acids in patients with SS?
20. Supplementation of fatty acids (omega-3) can be used,
since this is a low-risk intervention and promotes the
improvement of symptoms and of functional dry eye tests,
although the results have been controversial in different
studies77–82 (A).
Part  3.  Systemic  treatment  for  glandular  and  systemic
manifestations
Q9. What are the effectiveness and safety of hydroxychloro-
quine and immunosuppressants in the treatment of patients
with SS?
21. There is no evidence of signiﬁcant improvement in glan-
dular symptoms with the use of hydroxychloroquine in
SS. However, there is improvement of laboratory and
inﬂammatory parameters83–90 (A).
22. There is no evidence for the use of systemic immunosup-
pressants in treating symptoms of dryness. While some
open and controlled studies have shown improvement
in laboratory and inﬂammatory parameters, a high fre-
quency of adverse events precluded their use for dry
syndrome91–98 (B).temic manifestations will depend on the affected organ
and severity60 (D).
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Q10. What are the effectiveness and safety of biologic ther-
apies in the treatment of patients with SS?
24. Anti-TNF therapy is not indicated for the treatment of
glandular or systemic manifestations of SS99–102 (A).
25. Rituximab is effective in improving many  manifestations
in SS, as glandular involvement (A),  fatigue (A),  disease
activity (C),  immunological parameters (A), glandular lym-
phocytic inﬁltration, systemic manifestations, and quality
of life103–105
26. Rituximab is not indicated as sole treatment of the
symptoms of dryness. This drug is a therapeutic option
for systemic manifestations that failed conventional
treatment103–106 (C).  By clinical criteria, in selected cases,
rituximab can be considered for serious and speciﬁc glan-
dular manifestations, such as refractory parotiditis62 (D).
27. Abatacept106–109 (C) and belimumab110 (C) are promising
drugs to improve disease activity, immunological proﬁle
and quality of life. These drugs can be considered in the
treatment of SS in refractory cases and with high systemic
disease activity.
Q11. What is the treatment of articular manifestations,
myositis and fatigue in patients with SS?
28. Initial treatment of arthritis resulting from SS can be
carried out with hydroxychloroquine, with or without
low doses of glucocorticoids or NSAIDs for symptomatic
relief83 (C).  In case of treatment failure with hydroxy-
chloroquine, this drug can be replaced or associated with
methotrexate60,96 (D).  In those rare refractory cases under
an optimal methotrexate dosage, the use of rituximab is
recommended106 (C).
29. Myositis characterized by weakness, elevated creatine
kinase (CK) and electroneuromyographic changes should
initially be treated with prednisone. In those rare refrac-
tory cases, methotrexate is recommended (D).
30. Noninﬂammatory pattern arthralgia with diffuse pain in
the absence of myositis should be treated as a painful
ampliﬁcation syndrome, with analgesia and exercise,
with attention to the potential risk of worsening of dry-
ness, caused by a pharmacological adverse effect (D).
31. The treatment of fatigue includes the prescription
of aerobic exercise of moderate to high intensity
14 (B),  and a proper management of the underly-
ing disease. Different classes of drugs have been
tested and have not proved to be effective or safer,
because they have unacceptable rates of adverse events,
such as dehydroepiandrosterone (DHEA)111 (A), fatty
acids82 (A),  hydroxychloroquine89,90 (A), azathioprine94
(A),  leﬂunomide97 (A), mycophenolate98 (A) and anti-
TNF agents102 (A).  At the discretion of the clinician,
rituximab103–105,112 (A) may be a therapeutic option,
considering the evidence of inﬂammation and the impact
on functional capacity and quality of life.
Q12. What is the treatment of neurological manifestations
in the peripheral nervous system in patients with SS?
32. For the treatment of PNS involvement, the combination
of high-dose glucocorticoids (with subsequent tapering) 0 1 5;5 5(5):446–457
and an immunosuppressant (azathioprine, cyclophos-
phamide, mycophenolate) is recommended60,113,114 (C).
33. Patients with mononeuritis multiplex should start
a scheme of intravenous methylprednisolone and
cyclophosphamide113 (C).
34. Patients with ataxic polyneuropathy and sensory
ganglioneuronopathy have poorer responses to all
treatments113 (C).  Therefore, for these patients, the
association of IVIG to the therapeutic regimen with
glucocorticoids and immunosuppressive drugs is rec-
ommended, in an attempt to achieve a better clinical
response115 (C).
35. When no clinical improvement is observed in the
initial treatment, rituximab is recommended116 (C).
Patients with vasculitis and cryoglobulinemia have better
responses to rituximab116 (C).
36. IVIG is a therapeutic option for all types of PNS involve-
ment, when previous schemes failed115,117,118 (C).
37. Plasmapheresis should be reserved for severe cases refrac-
tory to all previous measures, since no studies were
published justifying its routine use119 (C).
Q13. What is the treatment of neurological manifestations
in the central nervous system in patients with SS?
38. For the treatment of CNS involvement, a combination
of glucocorticoids and cyclophosphamide at high doses
is recommended113,120–124 (C).  In the face of no clinical
improvement, rituximab is recommended60,125 (C).
39. Subacute febrile aseptic meningitis can be treated initially
solely with glucocorticoids, depending on the clinical
condition122 (C).
Q14. What is the treatment of pulmonary (parenchymal
and lower airways) manifestations in patients with SS?
40. In the presence of symptomatic interstitial pulmonary
disorder, treatment with glucocorticoids plus an immuno-
suppressive agent (azathioprine or cyclophosphamide)
is recommended126–129 (C).  Mycophenolate mofetil is an
option in refractory cases or in those patients with
contraindication to other immunosuppressive agents130
(C).  Rituximab may be considered in refractory cases
of interstitial pneumonia, and overtreatment of ﬁbrotic
changes related to the sequel should be avoided106
(C).
41. Bronchiolitis respiratory tract manifestations may be
mild, justifying only the use of inhaled and/or systemic
corticosteroid therapy131 (C).  Immunosuppressive drugs
should be according to specialist opinion60 (D).
Q15. What is the treatment of glomerular and tubulointer-
stitial renal manifestations in patients with SS?
42. Considering clinician opinion high-dose glucocorticoids
might be indicated, with or without association with other
immunosuppressive agents132–137 (C).43. In GNs, intravenous methylprednisolone in association
with cyclophosphamide is recommended132,133 (C).  Aza-
thioprine and cyclosporine may be options in mild to
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moderate cases132 (C).  Rituximab should be considered in
refractory cases106,132,137 (C).
Q16. What are the effectiveness and safety of drug therapy
n the treatment of vasculitis in patients with SS?
4. The recommended treatment for vasculitis, regardless of
the organ involved, is immunosuppression with high-
dose intravenous methylprednisolone for three days,
in combination with immunosuppressants (azathio-
prine, mycophenolate mofetil, or cyclophosphamide);
cyclophosphamide has been the most commonly used
immunosuppressant138–141 (C).  Treatment of cutaneous
vasculitis may be initially carried out with an oral glu-
cocorticoid (0.5–1 mg/kg/day) or with intravenous methyl-
prednisolone (depending on the severity of the condition)
plus an immunosuppressant. Cases refractory to initial
treatment can be treated with rituximab142,143 (C).
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razilian Society of Rheumatology.
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